Matinas Biopharma Holdings, Inc. (MTNB): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTNB Stock Price Chart Interactive Chart >
MTNB Price/Volume Stats
| Current price | $0.75 | 52-week high | $1.61 |
| Prev. close | $0.75 | 52-week low | $0.49 |
| Day low | $0.74 | Volume | 213,100 |
| Day high | $0.78 | Avg. volume | 682,709 |
| 50-day MA | $0.76 | Dividend yield | N/A |
| 200-day MA | $0.89 | Market Cap | 162.65M |
Matinas Biopharma Holdings, Inc. (MTNB) Company Bio
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections.
Latest MTNB News From Around the Web
Below are the latest news stories about Matinas BioPharma Holdings Inc that investors may wish to consider to help them evaluate MTNB as an investment opportunity.
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Topline Interim Data Expected Q3 2022 – – In Vivo Study of Orally Administered LNC Remdesivir Demonstrated Reduced Viral Titers and Effects Similar to Subcutaneous Administered Remdesivir; NIAID to Support an Additional Preclin |
Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ETBEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Tuesday, January 25, 2022 at 8:30 a. |
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis– DSMB evaluated both safety and efficacy data in recommending cohort progression – |
Analysts Predicting A Spike In Matinas BioPharma Holdings Inc. (AMEX: MTNB)?Matinas BioPharma Holdings Inc. (AMEX:MTNB) price on Wednesday, December 08, rose 9.90% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.11. A look at the stock’s price movement, the close in the last trading session was $1.01, moving within a range at $1.01 and $1.16. The beta … Analysts Predicting A Spike In Matinas BioPharma Holdings Inc. (AMEX: MTNB)? Read More » |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! |
MTNB Price Returns
| 1-mo | 6.38% |
| 3-mo | 30.62% |
| 6-mo | -28.57% |
| 1-year | -2.60% |
| 3-year | -21.88% |
| 5-year | -71.80% |
| YTD | -25.74% |
| 2021 | -25.74% |
| 2020 | -40.09% |
| 2019 | 281.51% |
| 2018 | -48.71% |
| 2017 | -17.14% |
Loading social stream, please wait...